The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

Blood

Volumn 103, Issue 11, 2004, Pages 4362-4364

  Lokhorst, Henk M ^a   Wu, Kalung ^a   Verdonck, Leo F ^a   Laterveer, Laurens L ^a   Van De Donk, Niels W C J ^a   Van Oers, Marinus H J ^a   Cornelissen, Jan J ^a   Schattenberg, Anton V ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRAFT REJECTION; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CELL TRANSPLANTATION; CHROMOSOME DELETION 13; CHRONIC GRAFT REJECTION; DONOR LYMPHOCYTE INFUSION; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 2542448169     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-11-3862     Document Type: Article

References (16)

1. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87:1196-1198.
2. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
3. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000;11:1179-1184.
4. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimares. Blood. 2004;103:767-776.
5. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
6. Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol. 2003;21:1728-1733.
7. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447-3454.
8. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT: European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
9. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation, second of two parts. N Engl J Med. 1975;292:895-890.
10. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100:2742-2747.
11. Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, et al. Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma. Clin Exp Immunol. 2003;131:340-346.
12. Krenger W, Hill GR, Ferrara JLM. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553-558.
13. Bellucci R, Wu CJ, Chiaretti S, et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004;103:656-663.
14. Boersma-Vreugdenhil GR, Peeters T, Bast BJ, Lokhorst HM. Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH. Blood. 2003;101:1653.
15. Konigsberg R, Zojer N, Ackermann J, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-812.
16. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.